Allogeneic Bone Marrow Transplantation (BMT) for Chronic Myelogeneous Leukemia (CML) in Chronic Phase (CP)

Allogeneic u4r seems to be a promising therapeutic modality for patients with CML. An actuarial 3-years disease-free survival of 60–70% can be achieved in patients grafted during CP of the disease (1, 2, 3). The results of BMT in accelerated phase and blastic phase of CML are poorer then in CP; the major problems are due to transplant-related complications (2) or to increased frequency of recurrent leukemia (3). This report summarizes the experience with allogeneic BMT performed during CP of CML at the Institute of Hematology of the University of Rame.